No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study

To assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC we...

Descripción completa

Detalles Bibliográficos
Autores principales: Burlacu, Ruxandra, London, Jonathan, Fleury, Audrey, Sené, Thomas, Diallo, Abdourahmane, Meyssonnier, Vanina, Zeller, Valérie, Galland, Joris, Huscenot, Tessa, Rubenstein, Emma, Trouiller, Pierre, Amathieu, Roland, Kutter, Johannes, Blondeel, David, Lejour, Gabriel, Mouly, Stéphane, Lidove, Olivier, Wladimir, Mauhin, Sène, Damien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154429/
https://www.ncbi.nlm.nih.gov/pubmed/34032722
http://dx.doi.org/10.1097/MD.0000000000026023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154429/
https://www.ncbi.nlm.nih.gov/pubmed/34032722
http://dx.doi.org/10.1097/MD.0000000000026023

Ejemplares similares